← Search & browse all drugs

sincalide

V04CC03

Forms & Strengths

Injectable solution 0.5 µg/mL (CCK‑8)
Single‑dose vials for IV administration

Adult Dosing

0.5 µg/kg IV bolus (max 50 µg) for HIDA gallbladder ejection fraction
0.02‑0.05 µg/kg IV over 1 min followed by 0.5 µg/kg infusion over 30 min for pancreatic secretion test

Pediatric Dosing

0.5 µg/kg IV bolus (max 10 µg) for HIDA imaging
0.025 µg/kg/min IV infusion for 30 min for pancreatic function assessment

Indications

Diagnostic gallbladder ejection fraction (HIDA scan)
Assessment of pancreatic exocrine function
Stimulation of bile flow for biliary imaging

Mechanism of Action

Synthetic CCK‑8 agonist of CCK‑A (CCK1) receptors
Induces gallbladder contraction and sphincter of Oddi relaxation
Stimulates pancreatic enzyme secretion

Contraindications

Known hypersensitivity to sincalide or CCK
Intestinal obstruction
Severe acute pancreatitis

Adverse Reactions

Nausea and vomiting
Abdominal cramps/pain
Hypotension or flushing
Diarrhea
Headache
Allergic rash or anaphylaxis

Drug Interactions

Anticholinergics (e.g., atropine) may blunt gallbladder response
Opioids may reduce sphincter relaxation
Cholinergic agonists may potentiate effects
ACE inhibitors may augment hypotensive response

Curated Content: Needs Vetting Before Put to Clinical Use